155 related articles for article (PubMed ID: 38632477)
21. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy.
Kohashi Y; Arai T; Sugimoto C; Tachibana K; Akira M; Kitaichi M; Hayashi S; Inoue Y
Respiration; 2016; 92(4):220-228. PubMed ID: 27576553
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.
Lee HY; Jung SY; Jang JH; Ko J; Kim DW; Her M; Lee JH
Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004258
[TBL] [Abstract][Full Text] [Related]
23. A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
Bi Y; Rekić D; Paterniti MO; Chen J; Marathe A; Chowdhury BA; Karimi-Shah BA; Wang Y
J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):55-67. PubMed ID: 32949322
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of deep learning-based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis.
Nam JG; Choi Y; Lee SM; Yoon SH; Goo JM; Kim H
Eur Radiol; 2023 May; 33(5):3144-3155. PubMed ID: 36928568
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
[No Abstract] [Full Text] [Related]
26. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.
Nathan SD; Shlobin OA; Ahmad S; Urbanek S; Barnett SD
Chest; 2007 Mar; 131(3):657-663. PubMed ID: 17356077
[TBL] [Abstract][Full Text] [Related]
27. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.
Salisbury ML; Xia M; Zhou Y; Murray S; Tayob N; Brown KK; Wells AU; Schmidt SL; Martinez FJ; Flaherty KR
Chest; 2016 Feb; 149(2):491-498. PubMed ID: 26425858
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
29. Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis.
Goobie GC; Ford-Sahibzada CA; Fritzler MJ; Johannson KA; Fell CD
Respir Med; 2019 Jul; 153():85-90. PubMed ID: 31176275
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.
Allen RJ; Oldham JM; Jenkins DA; Leavy OC; Guillen-Guio B; Melbourne CA; Ma SF; Jou J; Kim JS; ; Fahy WA; Oballa E; Hubbard RB; Navaratnam V; Braybrooke R; Saini G; Roach KM; Tobin MD; Hirani N; Whyte MKB; Kaminski N; Zhang Y; Martinez FJ; Linderholm AL; Adegunsoye A; Strek ME; Maher TM; Molyneaux PL; Flores C; Noth I; Gisli Jenkins R; Wain LV
Lancet Respir Med; 2023 Jan; 11(1):65-73. PubMed ID: 35985358
[TBL] [Abstract][Full Text] [Related]
31. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
32. Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis.
Aussedat PH; Chebib N; Ahmad K; Glerant JC; Drevet G; Grima R; Maury JM; Nasser M; Thivolet-Bejui F; Traclet J; Turquier S; Chalabreysse L; Tronc F; Cottin V
Respiration; 2020; 99(12):1101-1108. PubMed ID: 33260187
[TBL] [Abstract][Full Text] [Related]
33. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
[TBL] [Abstract][Full Text] [Related]
34. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
[TBL] [Abstract][Full Text] [Related]
35. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.
Bahmer T; Kirsten AM; Waschki B; Rabe KF; Magnussen H; Kirsten D; Gramm M; Hummler S; Brunnemer E; Kreuter M; Watz H
BMC Pulm Med; 2017 Jul; 17(1):104. PubMed ID: 28743305
[TBL] [Abstract][Full Text] [Related]
36. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis.
Uehara M; Enomoto N; Mikamo M; Oyama Y; Kono M; Fujisawa T; Inui N; Nakamura Y; Suda T
Respir Med; 2016 May; 114():18-26. PubMed ID: 27109807
[TBL] [Abstract][Full Text] [Related]
37. Deep learning-based prognostication in idiopathic pulmonary fibrosis using chest radiographs.
Lee T; Ahn SY; Kim J; Park JS; Kwon BS; Choi SM; Goo JM; Park CM; Nam JG
Eur Radiol; 2024 Jul; 34(7):4206-4217. PubMed ID: 38112764
[TBL] [Abstract][Full Text] [Related]
38. Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis.
Park EH; Hwang WC; Lee Y; Lee EY; Lee EB; Song YW; Park JK
Int J Rheum Dis; 2019 Mar; 22(3):507-515. PubMed ID: 30548402
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis.
Cortes-Telles A; Forkert L; O'Donnell DE; Moran-Mendoza O
Can Respir J; 2014; 21(3):e55-60. PubMed ID: 24712014
[TBL] [Abstract][Full Text] [Related]
40. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
